Breaking News
The West Is Winning The Information War While Russia Prevails On The Battlefield
Iran-Oman Hormuz Route 'Agreed To' As Iran Warns Against US 'Interference'
EU To Use $1.62 Billion In Interest From Frozen Russian Assets To Support Ukraine
Futures Flat As Tech Slides After Memory Stocks, Korea Tumble
Top Tech News
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
Betavolt unveils revolutionary coin-size battery with nickel-63 nuclear isotope...
China claims it has built a 'nuclear drone' that can stay airborne forever
Canada just solved two giant infrastructure problems at exactly the same time.
Moderna's New mRNA Flu 'Vaccine' Wins FDA Approval
In what is difficult to frame, try as apologists might, as anything other than a fresh betrayal of the MAHA coalition for the benefit of the pharmaceutical industry at the expense of (actual) public health, the FDA has just approved a Moderna mRNA influenza "vaccine" (mRNA shots being more accurately described as gene therapy than conventional vaccines).
Via Reuters:
"The U.S. Food and Drug Administration has approved Moderna's (MRNA.O) flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine ?for seasonal flu.
The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older…
Moderna has agreed to run an additional study and submit more data in adults 65 and older to confirm the vaccine's benefit in that age group…
The approval was based on data from a ?late-stage trial involving more than 40,000 adults aged 50 and older, which showed the shot was ?26.6% more effective than a licensed standard-dose flu vaccine.
The company also submitted separate late-stage data showing the ?vaccine generated stronger antibody responses than Sanofi's high-dose flu vaccine in adults 65 and older.
MFlusiva would compete with flu vaccines from Sanofi (SASY.PA),, GSK (GSK.L), CSL Seqirus (CSL.AX),, and AstraZeneca (AZN.L)…
Jefferies analysts had forecast $750 million in U.S. sales of Moderna's flu shot and combination COVID-flu vaccine by 2030."
The mechanism of action for Moderna's new mRNA flu shot is identical to company's COVID product, save that the spike protein produced by the mRNA in the former has been swapped for the influenza protein hemagglutinin (HA) protein in the latter.
In other words, the same risk of synthetic foreign proteins floating around the body and getting lodged in tissues, thereby potentially provoking crippling autoimmune responses, remains.
What's more important than the inevitable death and suffering, though, is obviously that Moderna forecasts hundreds of millions of dollars in windfall profits over the next several years for the people who really matter: the shareholders.
You want to make an omelet, you gotta break some eggs (in women's ovaries).
And all decent people support that trade-off.
We're not communists, after all.